GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Median PS Value
中文

Corcept Therapeutics (Corcept Therapeutics) Median PS Value

: $37.12 (As of Today)
View and export this data going back to 2004. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Corcept Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.324. Corcept Therapeutics's 10-Year median PS Ratio is 8.5846. Therefore, the Median PS Value for today is $37.12.

As of today (2024-04-24), Corcept Therapeutics's share price is $23.00. Corcept Therapeutics's Median PS Value is $37.12. Therefore, Corcept Therapeutics's Price to Median PS Value for today is 0.62.

The historical rank and industry rank for Corcept Therapeutics's Median PS Value or its related term are showing as below:

CORT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58   Med: 0.73   Max: 0.88
Current: 0.62

During the past 13 years, the highest Price to Median PS Value of Corcept Therapeutics was 0.88. The lowest was 0.58. And the median was 0.73.

CORT's Price-to-Median-PS-Value is ranked better than
51.94% of 258 companies
in the Biotechnology industry
Industry Median: 0.66 vs CORT: 0.62

Corcept Therapeutics Median PS Value Historical Data

The historical data trend for Corcept Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 35.24 37.12

Corcept Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.24 34.01 34.00 34.98 37.12

Competitive Comparison

For the Biotechnology subindustry, Corcept Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics Price-to-Median-PS-Value Distribution

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Price-to-Median-PS-Value falls into.



Corcept Therapeutics Median PS Value Calculation

Corcept Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=4.324*8.5846
=37.12

10-Year Median PS Ratio is 8.5846.
Corcept Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.324.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corcept Therapeutics  (NAS:CORT) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Corcept Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=23.00/37.12
=0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corcept Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics (Corcept Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Executives
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer officer: Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb officer: CHIEF FINANCIAL OFFICER C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon officer: Chief Accounting Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck officer: See Remarks C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt officer: Chief Scientific Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff director, officer: CHIEF EXECUTIVE OFFICER 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr director, 10 percent owner 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer officer: Chief Medical Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025